Januvia diabetes treatment gets thumbs up

Januvia, the new diabetes treatment from Merck, has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP.) The CHMP is part of the European Medicines Evaluation Agency (EMEA.) The CHMP has recommended that Januvia be approved in the European Union to treat type 2 diabetes.
Januvia will now be submitted to the European Commission with an opinion attached. Januvia could then become the first and solo approved prescription drug in the DPP-4 inhibitor class. Merck are expected to await news of the decision with baited breath. A positive verdict will be good news for the diabetic community and healthcare services also.
If successful, the decision will apply across 27 countries. Approval for marketing is likely to be granted in April. In order to reach the decisio, the CHMP reviewed as much data as possible, based on clinical trials involving 4000 people.
Januvia should not be used by those patients who have type 1 diabetes or amongst those who have ketoacidosis. Merck and co operates in most countries as Merck, Sharp and Dohme.